natgillin/translations-raw huggingface dataset:
(1) If nucleotide or amino acid sequences are disclosed in the European patent application the description shall contain a sequence listing conforming to the rules laid down by the President of the European Patent Office for the standardised representation of nucleotide and amino acid sequences. 
(1) Če so v evropski patentni prijavi razkrita zaporedja nukleotidov ali aminokislin, vsebuje opis prikaz zaporedij, ki je v skladu s predpisi, ki jih je določil predsednik Evropskega patentnega urada za standardno predstavitev zaporedij nukleotidov in aminokislin.
(2) The President of the European Patent Office may require that, in addition to the written application documents, a sequence listing in accordance with paragraph 1 be submitted on a data carrier prescribed by him accompanied by a statement that the information recorded on the data carrier is identical to the written sequence listing. 
(2) Predsednik Evropskega patentnega urada lahko zahteva, da se poleg pisnih dokumentov prijave predloži tudi prikaz zaporedij, sestavljen v skladu s prvim odstavkom, na nosilcu podatkov, ki ga predpiše, in da se predloži izjava, da so podatki z nosilca podatkov enaki pisnemu prikazu zaporedij.
(3) If a sequence listing is filed or corrected after the date of filing, the applicant shall submit a statement that the sequence listing so filed or corrected does not include matter which goes beyond the content of the application as filed. 
(3) Če se prikaz zaporedij vloži ali popravi po datumu vložitve prijave, mora prijavitelj predložiti izjavo, da tako vloženi ali popravljeni prikaz zaporedij ne vključuje ničesar, kar bi presegalo vsebino prijave, kot je bila vložena.
(4) A sequence listing filed after the date of filing shall not form part of the description. 
(4) Prikaz zaporedij, ki je vložen po datumu vložitve prijave, ni del opisa.
Deposit of biological material 
Deponiranje biološkega materiala
(1) If an invention involves the use of or concerns biological material which is not available to the public and which cannot be described in the European patent application in such a manner as to enable the invention to be carried out by a person skilled in the art, the invention shall only be regarded as being disclosed as prescribed in Article 83 if: 
(1) Če izum vključuje uporabo biološkega materiala ali zadeva biološki material, ki ni dostopen javnosti in ga v evropski patentni prijavi ni mogoče opisati na način, da bi strokovnjak lahko izvedel izum, velja ta za razkritega, kot predpisuje 83. člen, samo:
(a) a sample of the biological material has been deposited with a recognised depositary institution not later than the date of filing of the application; 
(a) če je bil vzorec biološkega materiala deponiran pri priznani depozitni ustanovi najkasneje do datuma vložitve prijave;
(b) the application as filed gives such relevant information as is available to the applicant on the characteristics of the biological material; 
(b) če prijava, kot je bila vložena, vsebuje vse bistvene podatke o značilnostih biološkega materiala, ki so dostopni prijavitelju;
(c) the depositary institution and the accession number of the deposited biological material are stated in the application, and 
(c) če sta v prijavi navedeni depozitna ustanova in številka deponiranega biološkega materiala in
(d) where the biological material has been deposited by a person other than the applicant, the name and address of the depositor are stated in the application and a document is submitted satisfying the European Patent Office that the latter has authorised the applicant to refer to the deposited biological material in the application and has given his unreserved and irrevocable consent to the deposited material being made available to the public in accordance with this Rule. 
(d) kadar je biološki material deponirala oseba, ki ni prijavitelj, če sta v prijavi navedena ime in naslov deponenta in je Evropskemu patentnemu uradu predložen dokument, ki dokazuje, da je deponent pooblastil prijavitelja, da se v prijavi lahko sklicuje na deponirani biološki material, in da je dal absolutno in nepreklicno soglasje, da je deponirani biološki material lahko na razpolago javnosti v skladu s tem pravilom.
(2) The information referred to in paragraph 1(c) and, where applicable, (d) may be submitted 
(2) Podatki iz pododstavka (c) prvega odstavka in, kadar je primerno, iz pododstavka (d) prvega odstavka se lahko predložijo:
(a) within a period of sixteen months after the date of filing of the application or, if priority is claimed, after the priority date, this time limit being deemed to have been met if the information is communicated before completion of the technical preparations for publication of the European patent application; 
(a) v šestnajstih mesecih po datumu vložitve prijave ali po prednostnem datumu, če se zahteva prednost, pri čemer se šteje, da je bil ta rok upoštevan, če so podatki sporočeni pred zaključkom tehničnih priprav za objavo evropske patentne prijave;
(b) up to the date of submission of a request for early publication of the application; 
(b) do datuma predložitve zahteve za predčasno objavo prijave;
(c) within one month after the European Patent Office has communicated to the applicant that a right to inspect the files pursuant to Article 128, paragraph 2, exists. 
(c) v enem mesecu od dneva, ko je Evropski patentni urad sporočil prijavitelju, da ima pravico do vpogleda v dokumentacijo na podlagi drugega odstavka 128. člena.
The ruling period shall be the one which is the first to expire. 
Odločilni rok je tisti, ki prvi poteče.
The communication of this information shall be considered as constituting the unreserved and irrevocable consent of the applicant to the deposited biological material being made available to the public in accordance with this Rule. 
Sporočitev teh podatkov velja kot absolutno in nepreklicno soglasje prijavitelja, da se da deponirani biološki material na razpolago javnosti v skladu s tem pravilom.
(3) The deposited biological material shall be available upon request to any person from the date of publication of the European patent application and to any person having the right to inspect the files pursuant to Article 128, paragraph 2, prior to that date. 
(3) Od datuma objave evropske patentne prijave je deponirani biološki material na zahtevo dostopen vsakomur, pred tem datumom pa tistemu, ki ima na podlagi drugega odstavka 128. člena pravico do vpogleda v dokumentacijo.
Subject to paragraph 4, such availability shall be effected by the issue of a sample of the biological material to the person making the request (hereinafter referred to as “the requester“). 
Ob upoštevanju četrtega odstavka se dostop omogoči tako, da se vložniku zahteve izda vzorec biološkega materiala.
Said issue shall be made only if the requester has undertaken vis-à-vis the applicant for or proprietor of the patent not to make the biological material or any biological material derived therefrom available to any third party and to use that material for experimental purposes only, until such time as the patent application is refused or withdrawn or deemed to be withdrawn, or before the expiry of the patent in the designated State in which it last expires, unless the applicant for or proprietor of the patent expressly waives such an undertaking. 
Vzorec se izda samo, če je vložnik zahteve glede na prijavitelja ali imetnika patenta prevzel obveznost, da biološkega materiala ali iz njega pridobljenega biološkega materiala ne bo dal na razpolago tretji osebi in da ga bo uporabljal zgolj za raziskovalne namene, dokler patentna prijava ni zavrnjena ali umaknjena ali se ne šteje za umaknjeno ali preden je patent prenehal veljati v tistih imenovanih državah, v katerih najkasneje preneha, razen če se prijavitelj ali imetnik patenta izrecno ne odreče takemu prevzemu obveznosti.
The undertaking to use the biological material for experimental purposes only shall not apply in so far as the requester is using that material under a compulsory licence. 
Določba o prevzemu obveznosti, da bo biološki material uporabljal samo v raziskovalne namene, ne velja, če vložnik zahteve uporablja ta material na podlagi prisilne licence.
The term “compulsory licence“ shall be construed as including ex officio licences and the right to use patented inventions in the public interest. 
Za prisilne licence se štejejo tudi uradne licence in pravica do uporabe patentiranih izumov zaradi javnega interesa.
(4) Until completion of the technical preparations for publication of the application, the applicant may inform the European Patent Office that 
(4) Do zaključka tehničnih priprav za objavo prijave lahko prijavitelj sporoči Evropskemu patentnemu uradu, da bo
(a) until the publication of the mention of the grant of the European patent or, where applicable, 
(a) do objave omembe o podelitvi evropskega patenta ali, kadar je primerno,
(b) for twenty years from the date of filing if the application has been refused or withdrawn or deemed to be withdrawn, the availability referred to in paragraph 3 shall be effected only by the issue of a sample to an expert nominated by the requester. 
(b) dvajset let od datuma vložitve prijave, če je bila ta zavrnjena ali umaknjena ali se šteje za umaknjeno, dostop iz tretjega odstavka omogočen le z izdajo vzorca izvedencu, ki ga imenuje vložnik zahteve.
(5) The following may be nominated as an expert: 
(5) Kot izvedenec se lahko imenuje:
(a) any natural person provided that the requester furnishes evidence, when filing the request, that the nomination has the approval of the applicant; 
(a) vsaka fizična oseba, če vložnik zahteve ob vložitvi zahteve predloži dokaz, da se prijavitelj strinja z imenovanjem;
(b) any natural person recognised as an expert by the President of the European Patent Office. 
(b) vsaka fizična oseba, ki jo predsednik Evropskega patentnega urada prizna kot izvedenca.
The nomination shall be accompanied by a declaration from the expert vis-à-vis the applicant in which he enters into the undertaking given pursuant to paragraph 3 until either the date on which the patent expires in all the designated States or, where the application has been refused, withdrawn or deemed to be withdrawn, until the date referred to in paragraph 4(b), the requester being regarded as a third party. 
Skupaj z imenovanjem se predloži tudi izjava izvedenca, da prevzema obveznosti do prijavitelja po tretjem odstavku do datuma, ko varstvo patenta preneha v vseh imenovanih državah, če pa je bila prijava zavrnjena, umaknjena ali se šteje za umaknjeno, do datuma iz pododstavka (b) četrtega odstavka, s tem da se vložnik zahteve šteje za tretjo osebo.
(6) For the purposes of paragraph 3, derived biological material shall mean any material which still exhibits those characteristics of the deposited material which are essential to carrying out the invention. 
(6) Za namene tretjega odstavka pridobljeni biološki material pomeni vsak material, ki še kaže tiste značilnosti deponiranega materiala, ki so bistvene za izvedbo izuma.
The undertaking referred to in paragraph 3 shall not impede any deposit of derived biological material necessary for the purpose of patent procedure. 
Obveze iz tretjega odstavka niso ovira za deponiranje pridobljenega biološkega materiala, potrebnega za patentni postopek.
(7) The request provided for in paragraph 3 shall be submitted to the European Patent Office on a form recognised by that Office. 
(7) Zahteva iz tretjega odstavka se predloži Evropskemu patentnemu uradu na obrazcu, ki ga ta priznava.
The European Patent Office shall certify on the form that a European patent application referring to the deposit of the biological material has been filed, and that the requester or the expert nominated by him is entitled to the issue of a sample of that material. 
Evropski patentni urad na obrazcu potrdi, da je bila vložena evropska patentna prijava, ki se nanaša na deponiranje biološkega materiala, in da ima vložnik zahteve ali izvedenec, ki ga je ta imenoval, pravico do izdaje vzorca tega materiala.
After grant of the European patent, the request shall also be submitted to the European Patent Office. 
Zahteva se predloži Evropskemu patentnemu uradu tudi po podelitvi evropskega patenta.
(8) The European Patent Office shall transmit a copy of the request, with the certification provided for in paragraph 7, to the depositary institution as well as to the applicant for or the proprietor of the patent. 
(8) Evropski patentni urad pošlje kopijo zahteve s potrdilom, predvidenim v sedmem odstavku, depozitni ustanovi in prijavitelju ali imetniku patenta.
(9) The President of the European Patent Office shall publish in the Official Journal of the European Patent Office the list of depositary institutions and experts recognised for the purpose of this Rule. 
(9) Predsednik Evropskega patentnega urada objavi v Uradnem glasilu Evropskega patentnega urada seznam depozitnih ustanov in izvedencev, ki so priznani za namen tega pravila.
(1) If biological material deposited in accordance with Rule 28, paragraph 1, ceases to be available from the institution with which it was deposited because: 
(1) Če biološki material, ki je bil deponiran v skladu s prvim odstavkom 28. pravila, ni več na razpolago v ustanovi, pri kateri je bil deponiran, ker:
(a) the biological material is no longer viable, or 
(a) biološki material ni več vitalen ali
(b) for any other reason the depositary institution is unable to supply samples, 
(b) depozitna ustanova iz kakršnega koli drugega razloga ne more izdati vzorcev,
and if no sample of the biological material has been transferred to another depositary institution recognised for the purposes of Rule 28, from which it continues to be available, an interruption in availability shall be deemed not to have occurred if a new deposit of the biological material originally deposited is made within a period of three months from the date on which the depositor was notified of the interruption by the depositary institution and if a copy of the receipt of the deposit issued by the institution is forwarded to the European Patent Office within four months from the date of the new deposit stating the number of the application or of the European patent. 
in če noben vzorec biološkega materiala ni bil poslan drugi depozitni ustanovi, priznani za namene 28. pravila, pri kateri je še vedno na razpolago, se šteje, da dostopnost ni bila prekinjena, če se prvotno deponirani biološki material ponovno deponira v treh mesecih od datuma, ko je depozitna ustanova uradno obvestila deponenta o prekinitvi, in če je bila v štirih mesecih po ponovnem deponiranju Evropskemu patentnemu uradu poslana kopija potrdila o prejemu depozita, ki jo je izdala depozitna ustanova in v kateri je navedena številka prijave ali evropskega patenta.
(2) In the case provided for in paragraph 1(a), the new deposit shall be made with the depositary institution with which the original deposit was made; in the cases provided for in paragraph 1(b), it may be made with another depositary institution recognised for the purposes of Rule 28. 
(2) V primeru, predvidenem v pododstavku (a) prvega odstavka, se ponovni depozit opravi pri depozitni ustanovi, pri kateri je bil opravljen prvotni depozit; v primerih, predvidenih v pododstavku (b) prvega odstavka, se lahko opravi pri drugi depozitni ustanovi, ki je priznana za namene 28. pravila.
(3) Where the institution with which the original deposit was made ceases to be recognised for the purposes of Rule 28, either entirely or for the kind of biological material to which the deposited sample belongs, or where that institution discontinues, temporarily or definitively, the performance of its functions as regards deposited biological material, and the notification referred to in paragraph 1 from the depositary institution is not received within six months from the date of such event, the three-month period referred to in paragraph 1 shall begin on the date on which this event is announced in the Official Journal of the European Patent Office. 
(3) Če ustanova, pri kateri je bil opravljen prvotni depozit, ni več priznana za namene 28. pravila bodisi v celoti ali za tisto vrsto biološkega materiala, v katero spada deponirani vzorec, ali če ta ustanova začasno ali dokončno neha opravljati naloge v zvezi z deponiranimi biološkimi materiali in uradno obvestilo depozitne ustanove iz prvega odstavka ni bilo prejeto v šestih mesecih po tem dogodku, začne trimesečni rok iz prvega odstavka teči na datum, ko se ta dogodek objavi v Uradnem glasilu Evropskega patentnega urada.
(4) Any new deposit shall be accompanied by a statement signed by the depositor certifying that the newly deposited biological material is the same as that originally deposited. 
(4) Ob vsakem ponovnem deponiranju se predloži izjava, ki jo podpiše deponent in s katero se potrjuje, da je ponovno deponirani biološki material isti kot prvotno deponirani.
(5) If the new deposit has been made under the provisions of the Budapest Treaty on the International Recognition of the Deposit of Microorganisms for the Purposes of Patent Procedure of 28 April 1977, the provisions of that Treaty shall prevail. 
(5) Če se ponovni depozit opravi po določbah Budimpeštanske pogodbe o mednarodnem priznanju depozita mikroorganizmov za postopek patentiranja z dne 28. aprila 1977, prevladajo določbe te pogodbe.
Form and content of claims 
Oblika in vsebina patentnih zahtevkov
(1) The claims shall define the matter for which protection is sought in terms of the technical features of the invention. 
(1) Patentni zahtevki z navedbo tehničnih značilnosti izuma določajo predmet, za katerega se zahteva varstvo.
Wherever appropriate claims shall contain: 
Kadar koli je primerno, patentni zahtevki vsebujejo:
(a) a statement indicating the designation of the subject-matter of the invention and those technical features which are necessary for the definition of the claimed subject-matter but which, in combination, are part of the prior art; 
(a) izjavo, ki označuje predmet izuma in tiste tehnične značilnosti, ki so potrebne za določitev predmeta, za katerega se zahteva varstvo, vendar so v medsebojni povezavi že del prejšnjega stanja tehnike;
(b) a characterising portion - preceded by the expression “characterised in that“ or “characterised by“ - stating the technical features which, in combination with the features stated in sub-paragraph (a), it is desired to protect. 
(b) označevalni del, ki ga uvajajo besede “za katerega je značilno, da“ ali “katerega značilnost je“ in ki navaja tehnične značilnosti, za katere se želi varstvo v povezavi z značilnostmi, navedenimi v pododstavku (a).
(2) Without prejudice to Article metricconverterProductID82, a82, a European patent application may contain more than one independent claim in the same category (product, process, apparatus or use) only if the subject-matter of the application involves one of the following: 
(2) Brez vpliva na 82. člen lahko evropska patentna prijava vsebuje več kot en neodvisni patentni zahtevek iste kategorije (proizvod, postopek, naprava ali uporaba) le, če predmet prijave vključuje:
(a) a plurality of inter-related products; 
(a) množico medsebojno povezanih proizvodov;
(b) different uses of a product or apparatus; 
(b) različne uporabe proizvoda ali naprave;
(c) alternative solutions to a particular problem, where it is not appropriate to cover these alternatives by a single claim. 
(c) druge možne rešitve posameznega problema, kadar ni primerno, da se te zajamejo z enim samim patentnim zahtevkom.
(3) Any claim stating the essential features of an invention may be followed by one or more claims concerning particular embodiments of that invention. 
(3) Vsakemu patentnemu zahtevku, ki navaja bistvene značilnosti izuma, lahko sledi eden ali več patentnih zahtevkov, ki se nanašajo na posebne izvedbe tega izuma.
(4) Any claim which includes all the features of any other claim (dependent claim) shall contain, if possible at the beginning, a reference to the other claim and then state the additional features which it is desired to protect. 
(4) Vsak patentni zahtevek, ki vključuje vse značilnosti kakega drugega patentnega zahtevka (odvisni patentni zahtevek), se mora po možnosti na začetku sklicevati na ta drugi patentni zahtevek, nato pa morajo biti v njem navedene dodatne značilnosti, za katere se želi varstvo.
A dependent claim shall also be admissible where the claim it directly refers to is itself a dependent claim. 
Odvisni patentni zahtevek je prav tako dovoljen, če je patentni zahtevek, na katerega se neposredno nanaša, tudi sam odvisni patentni zahtevek.
All dependent claims referring back to a single previous claim, and all dependent claims referring back to several previous claims, shall be grouped together to the extent and in the most appropriate way possible. 
Vsi odvisni patentni zahtevki, ki se nanašajo na en sam prejšnji patentni zahtevek, in vsi odvisni patentni zahtevki, ki se nanašajo na več prejšnjih patentnih zahtevkov, morajo biti, kolikor je mogoče, razvrščeni v skupine na najustreznejši način.
(5) The number of the claims shall be reasonable in consideration of the nature of the invention claimed. 
(5) Število patentnih zahtevkov mora biti v razumnih mejah, pri čemer se upošteva narava izuma, za katerega se zahteva varstvo.
If there are several claims, they shall be numbered consecutively in Arabic numerals. 
Če je patentnih zahtevkov več, se po vrsti oštevilčijo z arabskimi številkami.
(6) Claims shall not, except where absolutely necessary, rely, in respect of the technical features of the invention, on references to the description or drawings. 
(6) Patentni zahtevki se glede tehničnih značilnosti izuma ne smejo sklicevati na opis ali skice, če ni res nujno.
In particular, they shall not rely on such references as: 
Zlasti se ne smejo nanje sklicevati z besedami, kot so:
“as described in part... of the description“, or “as illustrated in figure... of the drawings“. 
“kot je opisano v... delu opisa“ ali “kot je prikazano na... sliki skic“.
(7) If the European patent application contains drawings, the technical features mentioned in the claims shall preferably, if the intelligibility of the claim can thereby be increased, be followed by reference signs relating to these features and placed between parentheses. 
(7) Če evropska patentna prijava vsebuje skice, morajo tehničnim značilnostim, omenjenim v patentnih zahtevkih, če to olajšuje razumevanje patentnega zahtevka, po možnosti slediti sklicevalne oznake, ki se nanašajo na te značilnosti in so postavljene med oklepaje.
These reference signs shall not be construed as limiting the claim. 
Te sklicevalne oznake se ne razlagajo kot omejitev patentnega zahtevka.
Unity of invention 
Enotnost izuma
(1) Where a group of inventions is claimed in one and the same European patent application, the requirement of unity of invention referred to in Article 82 shall be fulfilled only when there is a technical relationship among those inventions involving one or more of the same or corresponding special technical features. 
(1) Če se varstvo za skupino izumov zahteva v eni in isti evropski patentni prijavi, je pogoj za enotnost izuma iz 82. člena izpolnjen le, če je med temi izumi tehnična povezava, ki vključuje eno ali več enakih ali podobnih posebnih tehničnih značilnosti.
The expression “special technical features“ shall mean those features which define a contribution which each of the claimed inventions considered as a whole makes over the prior art. 
Izraz “posebne tehnične značilnosti” pomeni tiste značilnosti, ki določajo prispevek, s katerim vsak od izumov, za katere se zahteva varstvo, kot celota nadgradi prejšnje stanje tehnike.
(2) The determination whether a group of inventions is so linked as to form a single general inventive concept shall be made without regard to whether the inventions are claimed in separate claims or as alternatives within a single claim. 
(2) Za določitev, ali je skupina izumov povezana tako, da tvori eno samo splošno izumiteljsko zamisel, ni pomembno, ali se varstvo za izume zahteva v ločenih patentnih zahtevkih ali kot različica v enem samem patentnem zahtevku.
Claims incurring fees 
Patentni zahtevki, za katere se plačujejo pristojbine